^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Avastin (bevacizumab)

    i
    Other names: RG-435, RO 4876646, R 435, RG435, R435, rhuMAb-VEGF, RO-4876646, RG 435, RO4876646, R-435
    Company:
    Roche
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    13h
    A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=72, Not yet recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide) • leucovorin calcium • risvutatug rezetecan (GSK5764227)
    13h
    Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) (clinicaltrials.gov)
    P2, N=50, Recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Jan 2029 | Trial primary completion date: Nov 2025 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab)
    14h
    Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=169, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Jan 2025
    Trial completion • Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type
    |
    Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    15h
    COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov)
    P1/2, N=61, Active, not recruiting, MedImmune LLC | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)
    19h
    Treatment strategies and innovation for recurrent high-grade glioma. (PubMed, J Neurooncol)
    Despite poor overall outcomes, incremental progress across targeted, immune, and delivery-based approaches supports a patient centered strategy emphasizing clinical-trial enrollment, molecular profiling and symptom focused care.
    Review • Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • IDH mutation + BRAF V600E
    |
    Avastin (bevacizumab) • temozolomide • lomustine
    19h
    Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. (PubMed, Ann Oncol)
    DUO-O met its primary PFS endpoints for first-line durvalumab plus carboplatin/paclitaxel and bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance versus carboplatin/paclitaxel and bevacizumab followed by bevacizumab in the non-tBRCAm HRD-positive and non-tBRCAm ITT populations. Further insight into long-term benefit is anticipated with additional follow-up.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel
    20h
    A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=62, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Sep 2028 --> Nov 2025
    Trial completion • Trial completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    23h
    Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer (clinicaltrials.gov)
    P4, N=75, Recruiting, Hebei Medical University Fourth Hospital | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Oct 2024 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Avastin (bevacizumab)
    1d
    Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, University of Cincinnati
    New trial
    |
    Avastin (bevacizumab)
    1d
    Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab (clinicaltrials.gov)
    P2, N=15, Recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna
    New P2 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    2d
    COATS-VEGF: Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease (clinicaltrials.gov)
    P3, N=18, Terminated, Fondation Ophtalmologique Adolphe de Rothschild | N=30 --> 18 | Suspended --> Terminated; Study futility based on the interim analysis
    Enrollment change • Trial termination
    |
    Avastin (bevacizumab)
    2d
    Molecularly guided precision therapy in metastatic adamantinoma: a case report. (PubMed, Per Med)
    She showed a sustained clinical response to fourth-line treatment with the PARP inhibitor olaparib, which lasted 15 months and led to improved performance status. Subsequent progression led to combination therapy with atezolizumab and bevacizumab, maintaining stable disease for eight months. Molecularly guided treatment resulted in an overall survival of 25 months.
    Journal • PARP Biomarker • PD(L)-1 Biomarker
    |
    XRCC2 (X-Ray Repair Cross Complementing 2)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab)